Last Updated: May 10, 2026

List of Excipients in Branded Drug TOVET (EMOLLIENT FORMULATION)


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing TOVET (EMOLLIENT FORMULATION)

Excipient Strategy and Commercial Opportunities for TOVET (Emollient Formulation)

Last updated: February 26, 2026

What is the excipient base for TOVET, and how does it enhance formulation stability?

TOVET is an emollient-based pharmaceutical product designed to improve skin hydration and barrier function. Its formulation relies on specific excipients that facilitate skin absorption, maintain stability, and ensure patient tolerability.

The primary excipients include:

  • Mineral oil (paraffin): Provides occlusion, prevents water loss, enhances emollient effects.
  • Petrolatum: Acts as a semi-permeable barrier, improving skin hydration.
  • Emollient esters such as isopropyl palmitate: Improve skin penetration and spreadability.
  • Preservatives like parabens or phenoxyethanol: Protect the formulation from microbial contamination.
  • Emulsifiers such as cetyl alcohol or stearyl alcohol: Stabilize the emulsion.

The formulation typically employs a hydrocarbon or silicone-based vehicle, optimizing both efficacy and stability. The excipient selection aligns with regulatory standards and consumer preferences for non-irritating, preservative-free products.

What are the key commercial considerations in excipient selection for TOVET?

Excipient choices influence manufacturing costs, shelf-life, regulatory approval, and consumer acceptance. Important considerations include:

  • Cost-effectiveness: Mineral oil, petrolatum, and common emollients are inexpensive and broadly available.
  • Regulatory approval: Excipients must have safety profiles acceptable across markets; mineral oil and petrolatum are established ingredients.
  • Stability: Hydrophobic excipients like petrolatum provide long-term stability, reducing degradation.
  • Consumer preferences: Preference shifts toward non-greasy, quick-absorbing formulations favor esters and light hydrocarbons.
  • Compatibility: Excipients must be compatible with active ingredients and packaging materials.

What are the emerging excipient trends that present commercial opportunity?

Innovation in excipients for topical formulations can create differentiation:

  • Bio-based emollients: Plant-derived esters (e.g., jojoba esters) appeal to a clean-label trend.
  • Silicone oils: Polydimethylsiloxanes enhance spreadability and create a non-greasy feel.
  • Humectants: Glycerin and sorbitol attract moisture, complementing occlusives.
  • Nanostructured carriers: Lipid nanoparticles or microemulsions improve skin penetration, especially for actives.

Investors and developers can leverage these trends by formulating TOVET with excipients that meet modern consumer demands without sacrificing stability or cost-efficiency.

What are the regulatory implications for excipient selection in TOVET?

Excipients must comply with regional regulations such as:

Region Regulatory Body Requirements Commonly Accepted Excipients
US FDA Generally Recognized as Safe (GRAS) Mineral oil, petrolatum, cetyl alcohol
Europe EMA Essential Principles, Pharmacopoeias Similar to US standards, plus plant-derived oils
Japan PMDA Phytotoxicity, Microbial limits Widely accepted excipients with clear safety data

Use of novel excipients may require pre-approval or safety data submission. The safety profile influences market access and patient perception.

How are patent strategies influenced by excipient choices?

Patent protection for TOVET can extend through:

  • Formulation patents: Covering specific excipient combinations or ratios.
  • Method of manufacturing: Innovative processes involving excipient integration.
  • Use patents: New indications or improved skin penetration based on excipient selection.

Patenting advantages arise from combining well-known excipients with novel delivery methods or using proprietary excipient blends to create a unique formulation profile.

What are the commercial risks linked to excipient sourcing and regulation?

Risks include:

  • Supply disruptions affecting manufacturing continuity.
  • Regulatory delays or restrictions on certain excipients, especially as safety standards tighten.
  • Price volatility for active excipients like esters and specialized oils.

Mitigation involves dual sourcing strategies, early regulatory engagement, and ongoing stability validation with selected excipients.

Key Takeaways

  • TOVET employs mineral oil, petrolatum, and emollient esters as core excipients for stability and efficacy.
  • Trends towards plant-based and silicone excipients offer market differentiation.
  • Regulatory compliance is vital; regional differences impact excipient choices.
  • Patent opportunities exist via formulation innovations and proprietary excipient blends.
  • Supply chain resilience and regulatory foresight mitigate commercial risks.

FAQs

Q1: Can TOVET formulations incorporate natural or plant-based excipients?
Yes, replacing traditional petroleum-based excipients with plant-derived esters or oils aligns with consumer preferences and regulatory shifts, providing differentiation.

Q2: What excipients can improve TOVET’s skin penetration?
Emollient esters such as isopropyl palmitate and silicone oils like dimethylsiloxane enhance skin absorption and spreadability.

Q3: How do excipients affect TOVET’s shelf stability?
Hydrophobic excipients like petrolatum and mineral oil inhibit oxidation and microbial growth, extending shelf life.

Q4: Are there regulatory barriers to novel excipients in TOVET?
Yes. Novel excipients require safety data and regulator approval, which may extend development timelines.

Q5: What market segments are most receptive to emollient formulations like TOVET?
Chronic skin conditions (eczema, psoriasis), personal care markets, and sensitive skin products exhibit high demand for emollient formulations.


References

[1] U.S. Food and Drug Administration. (2022). Inactive Ingredient Database. https://www.fda.gov/cosmetics/cosmetic-products/active-and-inactive-ingredients
[2] European Medicines Agency. (2021). Guideline on excipients in the label and packaging of medicinal products. EMA/CHMP.
[3] Korting, H.C., & Scholl, T. (2018). The importance of excipients in topical dermatological formulations. Journal of Dermatological Treatment, 29(8), 776–781.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.